Evidence map›Paper›PMID 39976030›Full record

ArticleCurrent drug delivery2025

A Nanocarrier Enhances the Anti-Liver Cancer Efficacy of Mitoxantrone: An Acidic

Yuzhen Ding, Panpan Wei, Die Xia, Mengyue Deng, Yingxi Zhang, Menglian Li, Zijun Yan, Tong Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Current drug delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuzhen DingSchool of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Yunnan, Kunming 650500, China.ORCID 0000-0002-5773-5441
Panpan WeiSchool of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Yunnan, Kunming 650500, China.
Die XiaSchool of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Yunnan, Kunming 650500, China.
Mengyue DengSchool of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Yunnan, Kunming 650500, China.
Yingxi ZhangSchool of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Yunnan, Kunming 650500, China.
Menglian LiSchool of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Yunnan, Kunming 650500, China.
Zijun YanSchool of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Yunnan, Kunming 650500, China.
Tong ChenSchool of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Yunnan, Kunming 650500, China.

Funding

Key project of Yunnan Key Laboratory of Pharmacology for Natural Products Open Fund YKLPNP-K2302National Health Commission of the People's Republic of China YLZLXZ24G039National Natural Science Foundation of China 81760698seventh batch of Yunnan University Engineering Research Center Project Construction Project [2019]-57Sichuan Provincial Administration of Traditional Chinese Medicine Research Project 2023MS057Sichuan Provincial Natural Science Foundation 2025ZNSFSC0684
6 · The paper itself

Abstract

introductionThe incidence and mortality rates of liver cancer are high; therefore, developing new drug delivery systems with good biocompatibility and targeting has become a research hotspot.

methodsMitoxantrone hydrochloride (MH) loaded in acidic Panax notoginseng polysaccharide III nanoparticles (MANPs) was prepared using electrostatic adsorption. This was achieved by loading MH in acidic

resultsFourier-transform infrared spectroscopy and differential scanning calorimetry indicated that MH in MANPs was amorphous and exhibited good encapsulation efficiency in the carrier. Findings from dynamic dialysis confirmed that MANPs exhibited slow drug release at pH 6.8 and over the pH range of 7.2-7.4. In vitro experiments confirmed the anti-tumor effects of MANPs on H22 cells based on the inhibition of cell proliferation and an increase in apoptosis. MANPs also demonstrated an obvious anti-tumor effect without any toxicity in H22 tumor-bearing mice. This effect could be attributed to APPN III enhancing the immune system and exerting a synergistic anti-tumor effect in combination with MH, thereby alleviating MH-induced damage to the immune system in H22 tumorbearing mice.

conclusionAs a nano-carrier prepared using natural resources, APPN III shows immense potential in the field of drug delivery and could serve as a novel option for the effective delivery of chemotherapeutic drugs.

Indexed as

Antineoplastic AgentsDrug CarriersLiver NeoplasmsMitoxantroneNanoparticlesPanax notoginsengPolysaccharidesAnimalsApoptosisCell Line, TumorCell ProliferationDrug LiberationHumansHydrogen-Ion ConcentrationMaleMiceAntineoplastic AgentsDrug CarriersMitoxantronePolysaccharidesanti-liver cancer therapy.combined medicationelectrostatic adsorptionenhanced permeability and retention effectmitoxantrone hydrochloridenano-drug delivery systemPanax notoginseng polysaccharide

Identifiers

PMID39976030

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.